mucos
surfac
interfac
host
intern
milieu
extern
environ
dual
function
serv
physic
barrier
foreign
bodi
pathogen
microb
provid
foundat
crucial
surviv
function
uptak
air
nutrient
reproduct
percept
signal
protect
mucos
surfac
ensur
special
mucosalassoci
lymphoid
tissu
malt
mucos
vaccin
contrast
parenter
vaccin
gener
induc
efficaci
protect
immun
reaction
induc
secretori
iga
respons
cellmedi
immun
mucos
tissu
portal
entri
mucos
pathogen
food
compon
inert
materi
breath
air
malt
remain
toler
caus
unnecessari
inflammatori
respons
despit
mani
advantag
mucos
vaccin
limit
number
licens
mucos
vaccin
almost
licens
mucos
vaccin
compos
whole
compon
pathogen
either
live
dead
success
subunit
mucos
vaccin
far
live
attenu
whole
cell
wc
kill
vaccin
formul
specif
adjuv
deliveri
system
vaccin
pathogenassoci
molecular
pattern
pamp
play
role
builtin
adjuv
cell
corpuscl
serv
deliveri
system
protect
antigen
could
mani
reason
sluggish
progress
develop
mucos
vaccin
concern
safeti
promin
reason
mucos
surfac
continu
expos
environment
food
antigen
allergen
inflammatori
immun
respons
mucos
vaccin
antigen
would
result
sustain
patholog
inflamm
case
nasal
vaccin
nasal
caviti
separ
central
nervou
system
thin
partit
olfactori
nerv
directli
project
brain
caviti
scarciti
optim
deliveri
system
anoth
reason
slow
progress
mucos
environ
mani
physicochem
condit
would
interfer
proper
stimul
immun
cell
antigen
adjuv
case
oral
administr
taken
microfold
cell
distal
jejunum
ileum
antigen
abl
accommod
low
ph
stomach
sudden
alkalin
surg
duodenum
abl
resist
proteolyt
attack
digest
enzym
contrast
oral
rout
antigen
deliv
intranas
experi
dramat
fluctuat
ph
abl
surviv
profus
mucos
secret
mucociliari
clearanc
rel
ineffici
antigen
uptak
antigenpres
cell
apc
effici
deliveri
mucos
vaccin
mani
new
deliveri
system
base
nanotechnolog
biomateri
studi
approv
clinic
use
vigor
clinic
orient
research
need
vaccin
formul
current
approv
clinic
trial
nanoscal
nm
carrier
alreadi
use
current
nanotechnolog
nanocarri
market
literatur
summar
immunostimul
complex
vlp
emuls
liposom
immunostimul
complex
iscom
polymer
nondegrad
nanoparticl
np
nanogel
np
abl
enter
apc
divers
pathway
therebi
differenti
modul
downstream
immun
respons
moreov
nanobas
deliveri
system
also
abl
carri
antigen
specif
adjuv
tlr
ligand
simultan
carrier
carrier
sometim
exert
adjuv
activ
nanoscal
vaccin
carrier
system
gener
constitut
three
key
compon
antigen
adapt
immun
respons
induc
adjuv
potenti
interact
innat
adapt
immun
system
react
antigen
deliveri
target
system
ensur
antigen
adjuv
deliv
togeth
right
locat
right
time
context
mani
effect
mucos
deliveri
system
use
nanomicroscal
carrier
activ
research
clinic
trial
level
recent
year
viralvector
vaccin
live
kill
viru
vaccin
alreadi
nanocarri
builtin
pamp
adjuv
vlp
virosom
behav
similarli
virus
stimul
immun
respons
carri
antigen
nanoscal
adjuv
formul
alreadi
compos
nanoscal
structur
formul
adjuv
vaccin
antigen
becam
inevit
modern
vaccin
develop
enhanc
immunogen
highli
purifi
antigen
insuffici
immunostimulatori
capabl
earli
adjuv
eg
aluminum
oilinwat
emuls
use
empir
rapidli
increas
knowledg
immun
system
interact
pathogen
allow
better
understand
figur
differ
micronanocarri
could
appli
develop
mucos
vaccin
deliveri
system
iv
current
new
approach
mucos
vaccin
deliveri
role
adjuv
formul
modern
vaccin
better
tailor
desir
clinic
benefit
interest
current
licens
oilinwat
emuls
adjuv
compris
nanoscal
structur
formul
squalen
popularli
incorpor
oilinwat
emuls
physic
immunostimulatori
properti
novarti
vaccin
diagnost
gsk
biolog
glucopyranosyl
lipid
adjuvantst
emuls
glase
infecti
diseas
research
institut
idri
squalen
content
around
ww
addit
emulsifi
agent
first
oilinwat
emuls
market
produc
microfluid
contain
sorbitan
trioleat
surfact
particl
size
around
nm
contain
surfact
particl
size
nm
glase
idri
consist
squalen
emuls
combin
gla
synthet
form
monophosphoryl
lipid
mpla
potent
immunopotenti
glase
particl
size
nm
suggest
emuls
particl
size
rang
nm
effici
taken
dendrit
cell
dc
henc
effect
stimul
immun
respons
coadminist
vaccin
antigen
tlr
ligand
immunostimulatori
agent
formul
oilwat
emuls
liposom
make
adjuv
vaccin
divers
infecti
agent
tumor
immunotherapi
iscom
approxim
cagelik
particl
produc
combin
protein
antigen
cholesterol
phospholipid
saponin
adjuv
quil
iscom
compos
matrix
serv
trap
protein
antigen
typic
membran
antigen
contain
hydrophob
domain
well
trap
iscom
apolar
interact
liposom
spheric
carrier
compos
one
phospholipid
membran
aqueou
core
thank
structur
liposom
provid
wide
rang
option
vaccin
formul
design
protein
peptid
dna
rna
adjuv
compon
readili
encapsul
insid
aqueou
core
embed
within
lipid
layer
attach
surfac
adsorpt
hydrophob
anchor
insert
coval
fusion
liposom
consid
nontox
biodegrad
mainli
phospholipid
use
sinc
normal
compon
mammalian
cell
membran
lipid
rel
nonimmunogen
liposom
could
design
manufactur
desir
physicochem
characterist
optim
induc
desir
immun
respons
vaccin
antigen
vesicl
size
lamellar
number
lipid
layer
surfac
charg
bilay
fluiditi
incorpor
immunostimulatori
compon
polymer
np
also
robustli
studi
deliv
vaccin
antigen
adjuv
polymer
np
submicrons
colloid
system
natur
synthet
polym
use
deliveri
carrier
chemic
drug
protein
peptid
nucleic
acid
owe
high
bioavail
control
releas
biodegrad
biocompat
properti
low
toxic
profil
compar
liposom
polymer
np
easili
incorpor
hydrophil
hydrophob
biomolecul
better
storag
stabil
commonli
studi
polym
poli
llactidecoglycolid
plg
polylactid
pla
poli
llactidecoglycolid
plga
biodegrad
biocompat
polym
well
character
approv
us
food
drug
administr
fda
use
human
excel
safeti
profil
extens
studi
formul
vaccin
antigen
protein
peptid
dna
etc
formul
antigen
either
entrap
adsorb
surfac
particl
protect
proteolyt
degrad
confer
longer
halfliv
vivo
notsodifficult
addit
engin
particl
regul
degrad
releas
cargo
adjuv
andor
antigen
wide
rang
rate
addit
polymer
particl
easili
pass
cell
reach
apc
malt
surviv
harsh
physicochem
condit
mani
mucos
compart
plg
polym
evalu
drug
deliveri
sinc
earli
use
wide
pharmaceut
medic
devic
applic
excel
safeti
profil
human
gener
plg
form
microparticl
rather
np
plg
microparticl
receiv
attent
vaccin
deliveri
world
health
organ
special
program
vaccin
develop
late
trigger
program
mani
antigen
tetanu
toxoid
hepat
b
antigen
diphtheria
toxoid
formul
plg
microparticl
evalu
comparison
aluminum
salt
adjuv
although
promis
result
plgbase
vaccin
small
anim
model
report
challeng
concern
antigen
stabil
insuffici
immun
respons
compar
alumadjuv
vaccin
prevent
use
plg
microparticl
commerci
vaccin
one
disadvantag
plg
polymerbas
vaccin
ineffici
transloc
lymph
node
apc
present
antigen
lymphocyt
particl
size
influenc
transport
specif
locat
cell
type
drain
lymph
node
np
nm
drain
lymph
node
local
lymphnoderesid
dc
macrophag
wherea
larger
particl
nm
mostli
associ
dc
inject
site
plg
particl
would
ineffici
present
antigen
dc
drain
lymph
node
regard
plg
microparticl
handicap
wide
appli
develop
vaccin
deliveri
system
pla
linear
aliphat
polyest
compos
lactic
acid
build
block
natur
occur
organ
acid
deriv
sugarcan
cornstarch
pla
physic
properti
tune
combin
racem
mixtur
enantiom
polyllactid
polydllactid
semicrystallin
amorph
polym
respect
thank
good
safeti
profil
plabas
product
approv
fda
european
medicin
agenc
ema
multipl
biomed
applic
polym
easili
chemic
modifi
differ
ligand
improv
specif
target
cell
vivo
pla
hydrolyz
acid
easili
metabol
bodi
via
kreb
cycl
pla
polym
fabric
microparticl
np
despit
physicochem
pharmaceut
advantag
pla
less
intens
appli
polym
copolym
plga
clinic
stage
vaccin
develop
although
consider
number
report
shown
use
pla
polym
np
versatil
vaccin
carrier
scalingup
laboratori
method
industri
product
face
hurdl
mostli
relat
particl
size
size
distribut
develop
pla
polym
clinicalgrad
vaccin
deliveri
system
practic
problem
need
solv
advanc
biodegrad
nanomicroparticl
plga
plgabas
polym
wide
explor
carrier
control
deliveri
macromolecular
therapeut
protein
peptid
vaccin
gene
antigen
growth
factor
plga
one
success
develop
biodegrad
polym
among
differ
polym
develop
formul
polymer
np
plga
strong
attent
owe
attract
properti
biodegrad
biocompat
fda
ema
approv
drug
deliveri
system
parenter
administr
welldescrib
formul
method
product
adapt
variou
type
drug
hydrophil
hydrophob
small
molecul
macromolecul
protect
drug
degrad
possibl
sustain
releas
possibl
modifi
surfac
properti
provid
stealthi
andor
better
interact
biolog
materi
possibl
target
np
specif
organ
cell
plgabas
carrier
cargo
releas
characterist
could
rel
well
control
modul
encapsul
particl
size
formul
addit
molecular
mass
ratio
lactid
glycolid
moieti
plga
surfac
morpholog
wide
use
plga
monom
composit
fastest
biodegrad
rate
complet
occur
approxim
day
polyglycolid
acid
hydrophil
polylactid
owe
absenc
methyl
side
group
higher
glycol
acid
percentag
caus
water
uptak
consequ
faster
degrad
plga
polym
plga
hydrolyz
origin
monom
lactic
acid
glycol
acid
byproduct
variou
metabol
pathway
associ
signific
toxic
except
lower
ph
next
releas
characterist
variou
physic
trait
plga
particl
manipul
includ
particl
size
size
distribut
zeta
potenti
polydispers
index
encapsul
effici
cargo
load
among
myriad
choic
nanomicrocarri
polym
plga
advantag
list
plga
particl
administ
via
divers
rout
plga
particl
formul
may
dampen
toxic
vaccin
compon
plga
particl
could
protect
antigen
degrad
allow
control
releas
plga
particl
could
made
target
apc
increas
crosspresent
antigen
plga
particl
allow
concomit
deliveri
multipl
vaccin
compon
dose
spare
mani
properti
plga
polym
favor
control
vaccin
deliveri
tool
drawback
well
plga
neg
effect
stabil
encapsul
protein
antigen
prepar
storag
primarili
owe
acidcatalyz
natur
degrad
hydrolysi
lead
accumul
lactic
glycol
acid
microenviron
denatur
encapsul
protein
antigen
consequ
compromis
immunogen
addit
process
condit
use
manufactur
plga
carrier
neg
effect
protein
secondari
structur
overcom
problem
associ
protein
degrad
mani
effort
made
optim
manufactur
process
add
excipi
would
protect
protein
antigen
encapsul
protein
antigen
adsorb
plga
particl
rel
protect
physicochem
insult
adsorb
antigen
would
offer
improv
stabil
activ
encapsul
antigen
avoid
exposur
organ
solvent
use
formul
acid
ph
condit
caus
degrad
polym
may
result
prematur
high
burst
releas
antigen
uptak
apc
lead
defici
immun
respons
natur
polym
attract
vaccin
deliveri
vehicl
owe
low
toxic
biocompat
synthet
polym
plga
pla
also
report
safe
biocompat
degrad
product
affect
microenviron
lower
ph
may
detriment
function
apc
compromis
immunogen
vaccin
antigen
hand
natur
polym
gener
compos
biolog
compon
make
physiolog
resorb
advers
effect
major
drawback
natur
polym
vaccin
deliveri
system
reproduc
overcom
technolog
research
two
major
group
natur
polym
use
manufactur
particul
carrier
peptideprotein
polyelectrolyt
includ
algin
chitosan
dextran
chitosan
chitosan
deriv
cation
polym
owe
structur
excel
mucoadhes
absorptionpromot
properti
chitosan
manufactur
alkalin
deacetyl
chitin
eg
deriv
commerci
exoskeleton
crustacean
fungi
linear
copolym
link
monom
dglucosamin
nacetyldglucosamin
biodegrad
biocompat
pka
primari
amin
group
chitosan
approxim
nascent
polym
neural
ph
carri
charg
henc
chitosan
insolubl
water
solubl
characterist
prevent
nascent
chitosan
abl
deliv
antigen
solubl
stabl
neutral
ph
structur
modif
made
chitosan
produc
deriv
solubl
neutral
ph
yet
retain
posit
charg
uniqu
properti
nascent
chitosan
chemic
modif
make
possibl
substitut
amin
hydroxyl
function
group
chitosan
variou
chitosan
deriv
produc
introduc
hydrophil
group
hydroxyalkyl
carboxyalkyl
succinyl
thiol
sulfat
graft
solubl
enhanc
polym
polyethylen
glycol
poloxam
watersolubl
deriv
ntrimethyl
carboxymethyl
deriv
chitosan
studi
extens
owe
rel
eas
synthesi
ampholyt
charact
ampl
applic
possibl
solubl
ntrimethyl
chitosan
mucoadhes
properti
excel
absorptionenhanc
effect
even
neutral
ph
cation
charg
neutral
ph
ntrimethyl
chitosan
rather
wide
appli
develop
mucos
vaccin
deliveri
system
sinc
mucoadhes
penetrationenhanc
abil
paracellular
rout
even
neutral
ph
chitosan
particl
fabric
success
deliv
adjuv
antigen
dc
tissu
drain
lymph
node
adjuv
antigen
could
either
incorpor
insid
adsorb
surfac
chitosan
microparticl
np
purpos
addit
carrier
chitosan
use
coat
polym
particl
enhanc
immunogen
bioadhes
surfac
adsorpt
potenti
ntrimethyl
chitosan
freeli
solubl
wide
ph
rang
compar
chitosan
deriv
bear
posit
charg
independ
environment
ph
methylcarboxi
chitosan
polyampholyt
polym
abl
form
viscoelast
gel
aqueou
environ
anion
macromolecul
neutral
ph
valu
basi
characterist
complex
two
chitosan
deriv
without
use
crosslink
could
gener
vaccin
deliveri
carrier
high
load
effici
maintain
integr
protein
antigen
algin
linear
anion
polysaccharid
found
cell
wall
brown
alga
high
affin
water
form
inert
highli
aqueou
environ
within
particl
limit
abil
carri
hydrophob
vaccin
antigen
adjuv
also
biocompat
biodegrad
easili
elimin
bodi
chitosan
particl
adsorpt
adjuv
onto
surfac
microspher
allow
differenti
releas
antigen
adjuv
tempor
control
stimul
immun
cell
algin
besid
role
vaccin
carrier
immunestimulatori
activ
though
stimul
signal
pathway
dextran
polysaccharid
compos
repeat
branch
glucos
molecul
commonli
use
form
dextran
sulfat
biocompat
hydrophil
decompos
natur
byproduct
anion
dextran
sulfat
often
fabric
cation
polylarginin
make
layerbylay
antigenadjuv
carrier
type
particl
assembl
layer
layer
multipl
antigen
adjuv
incorpor
multipl
layer
maxim
target
activ
immun
cell
selfassembl
peptid
report
use
candid
futur
vaccin
deliveri
system
peptid
molecul
ration
design
selfassembl
specif
nanoarchitectur
respons
chang
assembl
environ
includ
ph
temperatur
ionic
strength
interact
host
guest
molecul
could
manufactur
form
nanomicel
nanovesicl
nanofib
nanotub
nanoribbon
hydrogel
would
divers
rang
mechan
physicochem
properti
peptid
deliveri
system
may
potenti
advantag
liposom
np
sinc
compos
amphiphil
molecul
high
load
effici
low
antigen
leakag
biodegrad
high
permeabl
biomembran
target
cell
molecul
design
cellspecif
target
includ
adhes
ligand
receptor
recognit
ligand
peptidebas
antigen
design
often
multival
display
molecul
also
act
intracellular
transport
respond
chang
physiolog
environ
gener
selfassembl
peptid
nonimmunogen
serv
builtin
adjuv
fuse
antigen
peptid
adjuv
activ
close
relat
nanostructur
sinc
mutat
key
amino
acid
residu
selfassembl
domain
demolish
immunogen
selfassembl
peptid
vaccin
adjuvant
nanofib
selfassembl
peptid
vaccin
report
tcelland
specif
interact
well
note
suggest
novel
immunomodul
mechan
although
peptid
nanofib
vaccin
effici
taken
dc
subsequ
activ
vaccin
caus
reactogen
nonspecif
inflammatori
reaction
administr
site
nanogel
becam
promin
recent
vaccin
deliveri
system
term
nanogel
defin
refer
nanoscal
particl
nm
diamet
compos
physic
chemic
crosslink
bifunct
network
good
swell
capac
aqueou
environ
nanogel
high
cargo
load
capac
biocompat
biodegrad
cation
nanogel
adhes
epitheli
cell
surfac
serv
artifici
chaperon
protect
antigen
aggreg
denatur
load
antigen
subsequ
releas
nativ
form
captur
appropri
apc
nearbi
surfac
nanogel
rel
easi
modifi
specif
ligand
enabl
target
deliveri
specif
cell
tissu
nanogel
vaccin
formul
deliv
via
wide
rang
rout
parenter
oral
nasal
pulmonari
ocular
administr
nanogel
formul
variou
polysaccharid
chitosan
mannan
hyaluron
acid
dextrin
cycloamylos
pullulan
enzymat
synthes
glucogen
recent
year
pullulan
play
critic
role
develop
nanogel
system
vaccin
drug
deliveri
pullulan
aqueou
polysaccharid
synthes
yeastlik
fungu
aureobasidium
pullulan
consist
hundr
repeat
unit
maltotrios
trimer
pullulan
wide
use
divers
biomed
industri
easili
modifi
rather
simpl
chemic
reaction
nontox
nonmutagen
noncarcinogen
import
nonimmunogen
pullulan
hydrophob
cholesterol
becom
amphiphil
form
selfaggreg
cholesterolbear
pullulan
chp
form
complex
np
variou
protein
antigen
chp
selfassembl
water
np
encapsul
protein
antigen
intern
space
hydrophob
interact
complex
np
protect
intern
protein
antigen
physicochem
enzymat
degrad
serv
ideal
deliveri
vehicl
releas
payload
control
fashion
valuabl
characterist
chp
nanogel
artifici
molecular
chaperon
activ
protein
antigen
captur
denatur
form
chp
nanogel
revers
denatur
temperatur
presenc
revers
denatur
reagent
nanomatrix
nanogel
protect
denatur
protein
antigen
artifici
molecular
chaperon
help
proper
refold
releas
anoth
advantag
chp
target
abil
apc
chp
nanogel
protein
antigen
could
form
colloid
stabl
np
nm
diamet
relev
size
allow
effect
uptak
epitheli
cell
apc
moreov
chp
nanogel
modifi
cation
charg
cchp
ad
amin
group
chp
nanogel
cchp
nanogel
could
well
formul
protein
antigen
effect
carri
vaccin
antigen
neg
charg
nasal
epithelium
intranas
administr
posit
charg
cchp
nanogel
provid
effici
adhes
neg
charg
nasal
mucu
epithelia
lead
higher
level
sustain
deliveri
antigen
dc
inhabit
underneath
mucosa
import
cchp
vaccin
formul
could
induc
significantli
higher
immun
respons
without
adjuv
addit
cchp
nanogel
could
activ
immatur
dc
suggest
biolog
activ
adjuvantlik
activ
reason
cchp
direct
stimulatori
effect
innat
immun
cell
could
significantli
enhanc
immunogen
cargo
antigen
thought
improv
antigen
resid
time
nasal
caviti
lead
better
antigen
transport
nasal
dc
cchp
nanogel
carri
clostridium
botulinum
type
neurotoxin
heavychain
cterminu
bohca
bound
nasal
epitheli
cell
subsequ
endocytos
bohca
antigen
separ
nanogel
protein
exchang
sustain
releas
exocytosi
subsequ
taken
dc
mucosa
epitheli
cell
serv
reservoir
cargo
antigen
overt
cytotox
observ
neither
cchp
nanogel
cargo
bohca
antigen
taken
olfactori
bulb
brain
tissu
suggest
cchp
nanogel
system
safe
nasal
administr
chapter
nanodeliveri
mucos
vaccin
past
present
futur
gastrointestin
gi
infect
signific
global
health
challeng
especi
develop
countri
gi
infect
spread
via
rout
primarili
contamin
water
food
due
poor
sanit
social
infrastructur
efficaci
vaccin
polici
econom
way
solv
gi
infect
problem
public
health
perspect
oral
vaccin
gener
best
way
induc
secretori
immunoglobulin
siga
gi
tract
igg
antibodi
respons
system
compart
fact
oral
vaccin
wide
use
global
infant
children
nation
immun
program
oral
polio
vaccin
opv
develop
albert
sabin
sinc
sabin
opv
vaccin
sever
oral
vaccin
rotaviru
salmonella
typhi
vibrio
cholera
licens
market
vaccin
made
live
attenu
organ
kill
microbi
cell
yet
licens
subunit
oral
vaccin
market
continu
effort
develop
oral
vaccin
advantag
oral
vaccin
note
haitian
cholera
epidem
oral
vaccin
faster
way
contain
circul
infect
prevent
outbreak
septemb
terrorist
attack
threat
biolog
warfar
becam
highlight
worldwid
potenti
bioterror
agent
like
dissemin
either
aerosol
food
water
suppli
target
wide
mucos
surfac
respiratori
gi
tract
respect
consid
bioterror
agent
invad
gi
mucosa
oral
vaccin
induc
protect
immun
respons
rout
entri
gener
interest
frontlin
tool
biodefens
oral
vaccin
sever
advantag
better
patient
complianc
mass
immun
capabl
easi
administr
selfdeliveri
simplifi
product
storag
lower
product
cost
needleassoci
risk
injuri
carryov
infect
tabl
import
virtu
oral
vaccin
needlefre
painless
administr
need
train
personnel
administr
two
major
mucos
vaccin
rout
oral
intranas
compar
tabl
wide
use
oral
vaccin
sabin
opv
contribut
enorm
erad
poliomyel
worldwid
recent
despit
efficaci
opv
replac
inject
polioviru
vaccin
ipv
develop
countri
opv
like
replac
ipv
global
sever
come
year
live
polioviru
discov
stool
opv
vaccin
possibl
spread
infecti
materi
environ
anoth
seriou
concern
opv
rare
event
revers
virul
strain
vivo
could
caus
serou
iatrogen
vaccineassoci
paralyt
poliomyel
concern
appli
mucos
vaccin
use
live
attenu
organ
gener
oral
vaccin
regard
better
choic
inject
parenter
vaccin
product
econom
regulatori
perspect
oral
vaccin
better
complianc
fewer
advers
reaction
oral
vaccin
better
largescal
product
mass
vaccin
campaign
develop
countri
sinc
needl
requir
selfadministr
possibl
thermostabil
technolog
would
enabl
success
coldchainfre
vaccin
kill
well
live
attenu
formul
resourcepoor
set
develop
countri
thank
mani
virtu
oral
vaccin
success
opv
research
oral
vaccin
rather
long
histori
limit
number
oral
vaccin
product
becom
avail
mani
oral
vaccin
prove
efficaci
preclin
studi
fail
clinic
trial
liveattenu
vaccin
rotaviru
typhi
success
introduc
market
case
cholera
two
type
oral
cholera
vaccin
ocv
current
avail
wcrb
kill
wc
monoval
vaccin
recombin
b
subunit
rb
cholera
toxin
ct
dukor
kill
modifi
wc
bival
vaccin
without
b
subunit
shanchol
euvichol
morcvax
cholera
vaccin
posit
paperaugust
wwwwhoint
chapter
cholera
immun
develop
use
oral
cholera
vaccin
diseas
control
three
wc
vaccin
base
cholera
strain
dosag
although
wc
kill
cholera
vaccin
list
prove
efficaci
multipl
clinic
trial
mani
prototyp
kill
subunit
vaccin
could
put
market
suboptim
immunogen
oral
vaccin
strong
immunestimulatori
adjuv
optim
deliveri
strategi
drive
effect
innat
adapt
immun
respons
vaccin
antigen
achiev
optim
immunogen
dukor
huge
number
kill
emuls
extens
test
mani
vaccin
immun
rout
howev
literatur
rather
rare
find
success
test
result
oral
vaccin
infecti
diseas
employ
oilinwat
waterinoil
emuls
formul
adjuv
system
success
oral
tumor
vaccin
studi
show
antigen
complex
melanoma
antigen
heat
shock
protein
staphylococc
enterotoxin
incorpor
nanoemuls
small
size
nm
induc
efficaci
protect
immun
respons
compar
subcutan
administr
vaccin
antigen
deliv
insid
core
attach
outsid
shell
micel
depend
electrochem
properti
vaccin
formul
oral
immun
plapegpla
plgapegplga
copolym
micel
load
dna
encod
hcv
multipl
epitop
antigen
could
induc
satisfactori
immun
respons
copolym
show
innat
adjuv
activ
caus
signific
advers
reaction
micel
synthes
nanocarri
engin
penetr
mucu
taken
mucos
apc
howev
micel
may
propens
dissoci
dilut
lead
loss
load
antigen
clinic
trial
deliveri
system
develop
employ
liposom
focus
parenter
rout
still
continu
effort
develop
liposomebas
oral
deliveri
tool
convent
liposom
vulner
acid
gastric
juic
easili
digest
pancreat
lipas
also
intestin
bile
salt
destroy
phospholipid
membran
integr
lyse
liposom
result
prematur
releas
vaccin
antigen
tackl
problem
research
investig
differ
lipid
moieti
archaeal
lipid
bile
salt
liposom
membran
import
determin
adjuvant
liposom
surfac
charg
posit
charg
cation
liposom
demonstr
possess
strongest
adjuvant
compar
neutral
neg
charg
liposom
mucoadhes
promot
cation
surfac
charg
would
stronger
interact
neg
charg
gi
mucu
cation
liposom
also
better
adher
neg
charg
membran
cell
enterocyt
limit
flush
peristalsi
provid
better
chanc
intern
howev
greater
toxic
cation
anion
liposom
concern
recent
studi
report
cation
liposom
induc
necrosi
releas
damageassoci
molecular
pattern
caus
inflamm
vivo
extend
clinic
applic
liposom
carrier
oral
vaccin
improv
stabil
sustain
gi
tract
mucosa
surfac
modif
liposom
rigor
investig
addit
cholesterol
quil
saponin
liposom
result
gener
selfassembl
pentagon
dodecahedron
intrins
adjuv
properti
thu
earn
name
iscom
two
type
iscom
exist
first
classic
type
manufactur
entrap
protein
antigen
make
act
vaccin
antigen
deliveri
adjuv
system
second
type
refer
iscom
matric
contain
entrap
antigen
serv
codeliv
adjuv
later
formul
vaccin
antigen
earli
iscom
formul
could
evalu
human
limit
veterinari
use
owe
reactogen
quil
quil
later
replac
iscom
could
given
clinic
trial
purifi
natur
show
improv
safeti
profil
remain
activ
adjuv
iscom
wide
tri
divers
antigen
parenter
intranas
vaccin
studi
trial
oral
vaccin
rel
scarc
one
major
challeng
work
iscom
difficulti
associ
antigen
incorpor
context
mani
trial
use
iscom
matric
pure
adjuv
formul
vaccin
antigen
rather
incorpor
elicit
immun
respons
benefici
elicit
classic
iscom
use
unmodifi
iscom
adjuv
would
significantli
simplifi
product
howev
benefit
antigen
encapsul
import
key
success
oral
rout
might
lost
reason
iscom
matrix
adjuv
combin
enter
vaccin
antigen
use
boost
intranas
parenter
rout
oral
prime
antigen
antigen
adjuv
use
iscom
induct
efficaci
immun
respons
gi
tract
immun
protocol
employ
intellig
oral
inject
primeboost
regimen
incorpor
addit
coat
adjuv
tri
vlp
imit
threedimension
conform
real
viru
mimic
infect
authent
virus
moreov
vlp
engin
express
addit
antigen
target
epitop
repeat
array
vlp
studi
oral
vaccin
viru
tumor
antigen
vlp
oral
vaccin
induc
humor
cellular
immun
respons
system
mucos
compart
signific
antigenspecif
siga
respons
also
observ
vlp
could
also
express
plant
tissu
success
could
purifi
plant
tissu
lower
cost
hand
rather
crude
freezedri
plant
tissu
contain
vlp
could
directli
administ
oral
induc
protect
immun
respons
anim
suggest
possibl
develop
human
edibl
vaccin
use
vlp
express
plant
tissu
tomato
potato
synthet
particl
serv
versatil
oral
deliveri
tool
vaccin
antigen
adjuv
could
load
encapsul
conjug
adsorpt
advanc
polym
materi
chemistri
formul
technolog
differ
type
natur
synthet
np
activ
test
possibl
use
effect
oral
vaccin
deliveri
recent
technolog
enabl
overcom
previou
barrier
oral
vaccin
allow
better
target
antigen
adjuv
desir
tissu
locat
cell
particl
engin
releas
antigen
adjuv
upon
degrad
swell
diffus
polym
chang
electrostat
interact
product
particl
defin
size
architectur
chemic
properti
would
enabl
oral
deliveri
difficult
vaccin
rout
term
target
deliveri
thank
major
develop
nanotechnolog
biomateri
scienc
depend
upon
polym
choic
deliveri
system
provid
adjuv
activ
along
biocompat
biodegrad
extens
studi
biodegrad
polym
develop
oral
vaccin
nanocarri
pla
plga
algin
chitosan
case
oral
deliveri
greater
surfac
area
np
owe
small
size
would
allow
increas
absorpt
across
intestin
epithelium
furnish
reduc
dosag
administr
volum
hydrophil
np
gener
transport
enterocyt
wherea
hydrophob
polymer
np
better
transport
cell
oral
administ
pla
np
nm
reach
peyer
patch
pp
threestep
process
particl
first
entrap
mucu
cross
epitheli
barrier
take
place
exclus
cell
lead
accumul
pp
final
np
interact
underli
b
cell
dc
pp
tissu
three
step
occur
within
minut
furthermor
dc
engulf
np
induc
tlr
express
licens
clinic
use
mucos
vaccin
deliveri
nanocarri
abl
protect
payload
degrad
penetr
mucu
barrier
control
releas
antigen
adjuv
target
site
principl
properti
could
tune
alter
particl
size
surfac
chemistri
threedimension
architectur
wide
accept
particul
antigen
effici
traffick
across
mucosa
deliv
mucos
apc
solubl
antigen
uptak
particl
gi
tract
occur
primarili
via
cell
despit
controversi
particl
diamet
smaller
thought
better
chanc
taken
cell
meet
requisit
deliv
divers
vaccin
antigen
adjuv
specif
mucos
target
plga
surfac
characterist
extens
modifi
coat
ionic
surfact
polym
polyethylen
glycol
peg
sodium
dodecyl
sulfat
aminodextran
chitosan
polyethylen
imin
polyllysin
protamin
cetyltrimethylammonium
surfac
chemistri
plga
particl
also
alter
increas
diffus
mucu
uptak
cell
oral
deliveri
method
coat
antigenadjuvantload
plga
np
methacrylatebas
polym
eudragit
produc
gastricacidresist
microparticl
releas
payload
termin
ileum
ph
level
reach
higher
phsensit
polym
deriv
methyl
methacryl
methacryl
methacryl
acid
acryl
andor
dimethacryl
blend
plga
protect
payload
np
enzymat
attack
stomach
small
intestin
antigen
encapsul
plga
np
sequenti
coat
phasetransit
shield
layer
poli
methyl
methacryl
co
methyl
acryl
co
methacryl
acid
llactidecoglycolid
pmmmaplga
found
protect
antigen
gi
tract
achiev
target
vaccin
larg
intestin
hydroxypropyl
methylcellulos
phthalat
hpmcp
anoth
enter
coat
agent
shown
make
acidresist
np
plga
carri
helicobact
pylori
antigen
effect
induc
protect
immun
respons
induc
enhanc
protect
immun
respons
antigen
deliv
plga
carrier
plga
particl
function
mcelltarget
ligand
combin
stabil
agent
incorpor
mcelltarget
lectin
uea
lta
plga
np
would
enhanc
antigenspecif
immun
respons
arginineglycineaspart
rgd
ligand
bind
integrin
also
target
cell
pegyl
plga
np
graft
rgd
rgd
peptidomimet
ligand
show
significantli
increas
uptak
cell
enhanc
specif
igg
respons
claudin
one
member
integr
membran
protein
famili
express
primarili
tight
junction
also
serv
target
develop
mcellbind
nanocarri
one
studi
antigenload
porou
plga
microparticl
success
coat
watersolubl
chitosan
conjug
mcelltarget
peptid
result
microparticl
effect
reach
pp
cell
transcytosi
induc
balanc
immun
respons
phsensit
polymer
deliveri
system
employ
hydroxypropyl
methylcellulos
phthalat
hpmcp
could
attun
ad
thiol
group
select
releas
ileal
ph
condit
formul
mcellhom
peptid
cksthplsc
conjug
bmpb
antigen
attun
hpmcp
deliveri
pp
subsequ
adapt
immun
respons
could
significantli
enhanc
recent
research
oral
vaccin
deliveri
np
direct
toward
incorpor
mucoadhes
polym
mucoadhes
polym
prolong
retent
time
particl
mucu
steric
adhes
interact
coat
nonbioadhes
nanospher
poli
butadienemal
anhydridecoldopa
increas
particl
uptak
small
intestin
conjug
immunostimulatori
ligand
bioadhes
polym
induc
longerlast
mucos
system
immun
respons
entrap
antigen
bioadhes
poli
anhydrid
np
nm
coat
mannos
salmonella
flagellin
induc
potent
balanc
immun
respons
compar
noncoat
particl
chitosan
deriv
tri
oral
deliveri
protein
dna
vaccin
limit
solubl
chitosan
alkalin
neutral
ph
circumv
fabric
chitosan
graft
copolymer
acyl
alkyl
monomer
polymer
moieti
modif
quarter
thiolat
acyl
graft
result
copolym
higher
mucoadhes
strength
increas
hydrophob
interact
advantag
hydrophob
antigen
entrap
increas
solubl
alkalin
ph
higher
solubl
control
extend
releas
profil
consequ
confer
wider
applic
chitosan
deriv
oral
vaccin
deliveri
chitosan
deriv
mucoadhes
abil
stimul
immun
cell
either
directli
interact
cell
open
tight
junction
epitheli
cell
advantag
mention
chitosan
appli
manufactur
oral
deliver
np
coat
micronanocarri
made
synthet
natur
biopolym
algin
use
make
oral
vaccin
carrier
util
acid
resist
immunostimulatori
properti
order
overcom
chitosan
instabl
lowph
environ
cation
chitosan
np
coat
acidresist
algin
make
composit
carrier
algin
encapsul
chitosan
np
entrap
protein
antigen
prove
protect
payload
protein
antigen
dna
acid
attack
stomach
oral
administr
owe
acid
resist
properti
algin
also
use
encapsul
bacteri
cell
develop
oral
vaccin
singl
oral
dose
alginateencapsul
bcg
elicit
effect
longlast
mucos
system
immun
respons
coldchainfre
ocv
could
develop
encapsul
heatinactiv
bacteri
cell
algin
oral
vaccin
edwardsiella
brucella
aeromona
infect
also
develop
encapsul
algin
glucan
particl
porou
cell
wall
shell
manufactur
treat
baker
yeast
saccharomyc
cerevisia
seri
alkalin
acid
solvent
extract
situ
layerbylay
synthesi
electrostat
interact
dna
could
encapsul
high
densiti
protein
antigen
could
encapsul
glucan
particl
hydrat
lyophil
could
induc
signific
intestin
siga
cellular
respons
encapsul
antigen
follow
oral
vaccin
glucan
microparticl
target
enterocyt
cell
uptak
activ
secret
express
cytokin
receptor
major
compon
glucan
microparticl
fungal
pamp
signal
receptor
complement
receptor
express
dc
monocyt
neutrophil
although
efficaci
glucan
particl
oral
vaccin
carrier
well
prove
model
antigen
ova
bsa
applic
pathogen
microorgan
rel
rare
one
reason
limit
use
glucan
particl
manufactur
current
limit
liquid
formul
requir
coldchain
storag
therefor
optim
use
poorer
region
plantbas
oral
vaccin
advantag
tradit
vaccin
cost
safeti
scalabl
sinc
research
manufactur
edibl
plantbas
vaccin
carrot
soybean
tomato
rice
potato
tobacco
microbi
pathogen
antigen
heatlabil
toxin
b
subunit
ltb
enterotoxigen
escherichia
coli
cholera
toxin
b
subunit
ctb
antigen
yersinia
pesti
virus
hepat
b
viru
rotaviru
norwalk
viru
mani
convent
vaccin
wide
distribut
develop
countri
vaccin
urgent
need
high
product
cost
requir
better
infrastructur
one
problem
stand
way
wider
distribut
desper
need
vaccin
convent
cell
ferment
system
produc
recombin
protein
vaccin
antigen
often
expens
easili
scalabl
anoth
emerg
infecti
diseas
field
one
health
deal
zoonot
diseas
spread
anim
human
solut
may
use
plant
plant
cell
bioreactor
molecular
farm
becom
well
establish
product
vaccin
mani
proof
principl
import
proof
efficaci
accumul
continu
mucoric
one
innov
approach
oral
vaccin
deliveri
use
edibl
rice
carrier
chapter
plantbas
mucos
vaccin
deliveri
system
rice
seed
stabil
resist
digest
stomach
make
mucoric
attract
oral
vaccin
deliveri
system
first
report
cholera
toxin
b
subunit
ctb
could
express
rice
seed
much
ctb
per
seed
store
storag
organel
protein
bodi
oral
ingest
rice
seed
express
ctb
induc
ctbspecif
serum
igg
mucos
iga
antibodi
neutral
activ
rice
storagespecif
immun
respons
note
express
rice
ctb
protect
pepsin
digest
vitro
riceexpress
ctb
also
remain
stabl
thu
maintain
immunogen
room
temperatur
year
provid
month
protect
ctor
ltinduc
diarrhea
primari
immun
result
show
mucoric
vaccin
could
stockpil
longer
room
temperatur
could
wide
use
oral
vaccin
without
coldchain
manag
ricebas
oral
vaccin
develop
way
mani
infecti
diseas
noninfecti
diseas
allergi
autoimmun
alzheim
diseas
wide
use
form
whole
bacteri
cell
vaccin
cholera
typhoid
fever
liquid
suspens
lack
shelf
stabil
liquid
format
unsuit
storag
distribut
develop
countri
regard
stabl
solid
dosag
vaccin
platform
requir
vaccin
formul
tablet
capsul
would
provid
stabil
eas
handl
comparison
microparticl
np
capsul
significantli
larger
size
could
serv
reservoir
multipl
vaccin
adjuv
formul
subunit
wc
kill
oral
vaccin
current
deliv
capsul
tablet
live
attenu
salmonella
vaccin
vivotif
routin
deliv
entericco
format
capsul
could
manufactur
appropri
physic
size
averag
size
capsul
tablet
rang
mm
suitabl
administr
target
popul
enter
coat
tablet
capsul
could
protect
gastric
acid
endow
control
releas
properti
provid
facilit
deliveri
discret
locat
intestin
principl
capsul
allow
incorpor
mani
previous
introduc
deliveri
technolog
one
primari
deliveri
format
recent
tabletbas
oral
avian
influenza
vaccin
shown
elicit
strong
antivir
antibodi
tcell
respons
approach
util
nonrepl
adenoviru
type
vector
express
avian
flu
hemagglutinin
antigen
togeth
dsrna
agonist
among
choic
mucos
rout
vaccin
administr
nasal
deliveri
wide
employ
innov
research
eas
approach
less
harsh
physicochem
condit
nasal
caviti
compar
gi
tract
furthermor
nasal
vaccin
could
administ
without
profession
train
least
three
nasal
vaccin
licens
worldwid
fda
approv
flumist
live
attenu
trivalentquadrival
influenza
vaccin
fluenz
emaapprov
quadrival
influenza
vaccin
two
intranas
vaccin
manufactur
compani
medimmun
serum
institut
india
licens
monoval
nasovac
pandem
influenza
chapter
nasal
influenza
vaccin
besid
influenza
vaccin
nasal
rout
wide
studi
develop
mani
prophylact
therapeut
vaccin
infecti
diseas
allergi
cancer
alzheim
diseas
lifestylerel
diseas
human
nasal
caviti
attract
rout
mucos
immun
total
surfac
area
cm
volum
ml
nasal
caviti
divid
five
anatom
function
region
nasal
vestibul
atrium
respiratori
region
olfactori
region
nasopharynx
respiratori
region
nasal
deliveri
drug
vaccin
occur
sinc
permeabl
region
larg
surfac
area
rich
vascular
bed
respiratori
region
cover
pseudostratifi
epithelium
compos
columnar
cell
interspers
goblet
cell
interconnect
tight
junction
zona
occluden
tight
junction
rel
resist
paracellular
passag
particul
materi
breath
air
respiratori
region
mucu
product
activ
take
place
mucu
layer
nasal
tract
rel
thinner
mucos
surfac
nasal
caviti
equip
nasopharyngealassoci
lymphoid
tissu
nalt
highli
similar
peyer
patch
ileum
nalt
also
cover
cell
activ
antigen
sampl
capac
intraepitheli
dc
project
dendrit
toward
mucos
lumen
sampl
antigen
particul
antigen
preferenti
sampl
cell
small
solubl
antigen
access
epithelium
captur
intraepitheli
dc
chapter
anatom
uniqu
mucos
immun
system
galt
nalt
ibalt
induct
regul
mucos
immun
toler
mucociliari
clearanc
mechan
neg
effect
nasal
vaccin
rapid
turnov
mucu
minut
fast
mucu
flow
mmmin
nasal
caviti
limit
length
resid
administ
vaccin
continu
outward
movement
cilia
epitheli
apic
surfac
acceler
clearanc
mucustrap
substanc
make
matter
wors
nasal
enzym
local
ph
neg
affect
stabil
nasal
administ
vaccin
antigen
could
live
attenu
influenza
vaccin
prove
effect
clinic
trial
approv
fda
ema
live
influenza
viru
abl
surviv
nasal
mucosa
har
builtin
adjuv
inactiv
split
influenza
vaccin
also
test
nasal
deliveri
prove
ineffect
without
coformul
appropri
mucos
adjuv
achiev
equival
antibodi
respons
without
adjuv
inactiv
split
antigen
given
least
three
time
inactiv
whole
viru
immun
given
even
inactiv
viru
antigen
requir
potent
mucos
adjuv
achiev
optim
immun
respons
system
mucos
compart
protein
antigen
employ
even
stronger
mucos
adjuv
effect
nasal
vaccin
mani
mucos
adjuv
suggest
formul
partner
nasal
vaccin
antigen
ct
relat
e
coli
heatlabil
toxin
lt
mutant
deriv
wide
tri
mucos
adjuv
preclin
studi
although
enterotoxin
serv
potent
adjuv
nasal
vaccin
divers
antigen
anim
studi
seldom
adopt
develop
human
nasal
vaccin
use
enterotoxin
nasal
vaccin
adjuv
seriou
failur
histori
subunit
influenza
nasal
vaccin
nasalflu
berna
adjuv
e
coli
lt
significantli
connect
bell
palsi
odd
ratio
epidemiolog
studi
switzerland
vaccin
consequ
withdrawn
market
advers
effect
could
relat
capac
ltb
ctb
subunit
bind
gangliosid
express
neuron
cell
retrograd
transloc
toward
brain
sinc
nasal
caviti
brain
separ
thin
anatom
structur
directli
connect
olfactori
nerv
bind
vaccin
compon
olfactori
nerv
contribut
neurotox
context
nasal
vaccin
adjuv
deliveri
system
must
clear
safeti
concern
introduc
market
given
versatil
eas
nasal
vaccin
numer
research
group
studi
safe
nasal
adjuv
could
replac
ct
lt
pamp
wide
studi
altern
nasal
adjuv
recent
publish
literatur
show
ligand
sting
agonist
ligand
could
use
effect
safe
nasal
adjuv
vaccin
antigen
remain
suffici
stabl
nasal
mucosa
abl
reach
antigencaptur
cell
surviv
mucociliari
clearanc
mechan
overcom
hurdl
micronanocarri
nasal
vaccin
deliveri
activ
research
increas
resid
time
mucos
surfac
sever
strategi
develop
increas
adhes
antigen
deliveri
system
nasal
mucu
howev
mucu
static
barrier
continu
secret
clear
nasal
caviti
cilia
beat
columnar
epitheli
cell
mucoadhes
abil
deliveri
carrier
would
caus
earlier
remov
vaccin
antigen
mucociliari
clearanc
mechan
intact
cope
problem
nasal
vaccin
carrier
cross
mucu
layer
rapidli
deliv
antigen
cell
dc
rather
strongli
adher
strategi
prevent
vaccin
interact
henc
allow
free
diffus
mucopenetr
effect
induc
efficaci
immun
respons
howev
mani
report
claim
mucoadhes
np
effect
enhanc
efficaci
mucos
vaccin
one
studi
show
mucoadhes
np
disrupt
protect
human
mucu
barrier
alter
microstructur
disrupt
microstructur
result
increas
mucu
mesh
pore
size
disrupt
mucu
mesh
would
allow
increas
passag
np
reach
epithelium
compar
advantag
disadvantag
intranas
vaccin
summar
tabl
outstand
advantag
eas
administr
safeti
issu
essenti
problem
resolv
nanoemuls
owe
stabil
small
droplet
size
optim
solubil
properti
great
potenti
nasal
drug
deliveri
furthermor
may
act
activ
adjuv
nasal
vaccin
formul
despit
promis
result
vitro
anim
studi
applic
nanoemuls
nasal
deliveri
human
appear
hinder
mainli
lack
detail
toxicolog
studi
lack
extens
clinic
trial
cation
nanoemuls
formul
could
facilit
cellular
uptak
model
antigen
ovalbumin
nasal
epitheli
cell
line
intranas
vaccin
hiv
immunogen
formul
oilinwat
nanoemuls
induc
robust
serum
igg
system
cellular
immun
respons
larg
number
studi
investig
potenti
liposom
deliveri
system
nasal
vaccin
peptid
protein
dna
success
carri
liposom
neutral
neg
posit
charg
cation
liposom
shown
interact
effici
epitheli
cell
dc
induct
cellmedi
immun
anoth
import
featur
liposomemedi
adjuvant
intranas
administr
dna
vaccin
formul
cation
liposom
togeth
gmcsfexpress
plasmid
result
high
level
antibodi
fece
serum
high
level
hivspecif
ctl
respons
use
characterist
liposom
deliveri
system
success
antitumor
cellular
immun
respons
could
induc
intranas
immun
dctarget
liposom
carri
tumor
antigen
similarli
intranas
immun
liposomeencapsul
plasmid
dna
encod
influenza
viru
hemagglutinin
elicit
mucos
cellmedi
humor
iga
igg
immun
respons
intranas
chitosan
solut
formul
report
enhanc
protect
immun
respons
mani
antigen
includ
diphtheria
pertussi
influenza
chitosan
solut
seem
induc
balanc
respons
neutral
antibodi
whole
influenza
viru
formul
trimethyl
chitosan
show
much
closer
interact
epitheli
surfac
potenti
gener
enhanc
uptak
induct
immun
respons
minim
local
toxic
term
ciliari
beat
frequenc
nasal
caviti
chitosan
dri
power
salt
form
enabl
thermal
stabl
vaccin
formul
requir
cold
chain
chitosan
power
formul
shown
outperform
solut
elicit
humor
respons
diphtheria
anthrax
noroviru
chitosan
microparticl
np
robustli
studi
intranas
deliveri
vaccin
chitosan
particl
basic
mucoadhes
abl
deliv
adjuv
antigen
cargo
effici
promot
humor
cellular
immun
respons
protein
peptid
antigenload
chitosan
particl
taken
apc
administr
site
eventu
traffick
drain
lymph
node
tcell
activ
occur
use
better
intranas
deliveri
chitosan
chemic
modifi
better
solubl
stabil
mucoadhes
safeti
resili
degrad
chitosan
show
strong
adhes
mucos
surfac
provid
longer
retent
time
nasal
mucosa
disrupt
tight
junction
nasal
epitheli
cell
lead
enhanc
paracellular
transport
antigen
paracellular
transport
vaccin
formul
nasal
mucosa
would
lead
enhanc
antigen
uptak
present
apc
consequ
augment
adapt
immun
demonstr
subunit
influenza
vaccin
studi
show
protect
heterolog
viral
challeng
ntrimethyl
chitosan
nasal
vaccin
formul
superior
plga
np
induc
nasal
iga
respons
improv
mucos
iga
humor
igg
antibodi
respons
gener
observ
mice
well
anim
model
rat
rabbit
cation
chitosan
enhanc
respons
well
dc
matur
type
interferon
induct
cgasst
pathway
suggest
involv
multipl
immun
compon
modifi
chitosan
particl
gener
improv
deliveri
effici
target
pegyl
improv
water
solubl
stabil
conjug
antigen
chitosan
coat
poli
np
induc
enhanc
mucos
immun
respons
coformul
influenza
antigen
protein
antigenload
pluron
microparticl
show
improv
antigen
releas
induc
higher
antigenspecif
secretori
iga
respons
intranas
vaccin
ovaload
trimethyl
acid
np
demonstr
superior
immunogen
intranas
immun
mannosyl
chitosan
particl
enhanc
macrophag
target
antigenspecif
secretori
iga
respons
mucos
secret
intranas
immun
chitosan
applic
intranas
vaccin
alreadi
reach
clinic
trial
stage
phase
form
np
antigenconjug
noroviru
vlp
formul
mpla
administ
intranas
twice
healthi
volunt
induc
specif
iga
respons
vaccin
individu
clinic
studi
test
intranas
vaccin
neisseria
meningitidi
serogroup
c
polysaccharid
mcp
conjug
antigen
mix
chitosan
show
specif
iga
respons
nasal
wash
balanc
respons
serum
despit
sever
clinic
studi
promis
result
chitosanbas
product
intranas
vaccin
yet
reach
market
influenza
viral
antigen
encapsul
within
bioadhes
starch
propylacryl
acid
mixtur
induc
signific
system
antigenspecif
igg
respons
mucos
iga
intranas
deliveri
influenza
vaccin
rabbit
inactiv
influenza
antigen
posit
charg
np
test
phase
clinic
studi
signific
mucos
iga
antibodi
produc
individu
receiv
twodos
nasal
immun
cation
maltodextrin
np
cation
surfac
anion
lipid
core
show
longer
nasal
resid
time
nasal
administr
liposom
plga
np
plga
np
use
synthet
polym
nasal
vaccin
deliveri
studi
cation
modif
plga
enhanc
resid
time
mucosa
result
better
immun
respons
higher
serum
antibodi
siga
level
surfac
modif
plga
carrier
chitosan
increas
mucoadhes
chang
zeta
potenti
neg
posit
without
affect
particl
size
dispers
moreov
clearanc
rate
nasal
caviti
reduc
result
enhanc
system
mucos
antibodi
respons
mani
antigen
encapsul
plga
nanomicroparticl
immun
nasal
rout
show
enhanc
immun
respons
system
mucos
immun
compart
ovalbumin
bovin
serum
albumin
bovin
parainfluenza
viru
bovin
syncyti
viru
hbsag
malaria
swine
fever
viru
pesti
streptococcu
equi
target
effici
cell
could
also
achiev
function
particl
surfac
although
mani
type
nanogel
test
vaccin
deliveri
system
cholesteryl
groupbear
pullulan
chp
extens
studi
one
mucos
vaccin
deliveri
cation
chp
cchp
nanogel
bind
better
epitheli
cell
subsequ
taken
high
effici
cell
cchp
nanogel
activ
dc
biolog
activ
adjuv
activ
howev
vigor
neutral
serum
igg
siga
respons
note
without
coadministr
mucos
adjuv
cchp
nanogel
suggest
univers
proteinbas
antigen
deliveri
vehicl
adjuvantfre
intranas
vaccin
chapter
nanodeliveri
vehicl
mucos
vaccin
potenti
immun
respons
cargo
antigen
cytokin
adjuv
could
coencapsul
chp
nanogel
encapsul
nanogel
act
vaccin
adjuv
nasal
influenza
vaccin
antiobes
vaccin
studi
cchp
engin
carri
adjuv
cyclic
digmp
along
selforigin
antigen
ghrelin
peptid
hormon
conjug
carrier
protein
pspa
cchpbase
nasal
vaccin
success
test
use
sever
infecti
diseas
lifestylerel
diseas
influenza
streptococcu
pneumonia
c
botulinum
obes
hypertens
anoth
promis
virtu
cchp
nanogel
nasal
deliveri
system
safeti
shown
reiter
protein
antigen
carri
nanogel
accumul
olfactori
bulb
brain
thu
exclud
risk
neurotox
brain
damag
physicochem
biolog
immunolog
characterist
consid
cchp
nanogel
platform
seem
promis
nasal
deliveri
system
translat
aggress
clinic
applic
although
mucos
vaccin
mani
advantag
limit
number
mucos
vaccin
licens
wide
test
vaccin
rout
oral
intranas
current
licens
oral
intranas
vaccin
compos
predominantli
wc
kill
live
attenu
microorgan
cell
bodi
serv
deliveri
system
whose
cell
compon
act
builtin
adjuv
futur
mucos
vaccin
made
purifi
antigen
compon
requir
safe
efficaci
adjuv
deliveri
system
recent
develop
biomateri
nanotechnolog
enabl
mani
innov
mucos
vaccin
trial
oral
vaccin
vaccin
deliveri
system
abl
stabli
carri
antigen
adjuv
resist
harsh
physicochem
condit
stomach
intestin
tract
besid
mani
nanomicrocarri
tool
gener
use
natur
chemic
materi
develop
oral
vaccin
deliveri
system
use
food
materi
robustli
research
expand
vaccin
coverag
gi
infect
develop
countri
intranas
vaccin
vaccin
deliveri
system
surviv
activ
mucociliari
clearanc
mechan
provid
safeti
given
anatom
locat
nasal
caviti
separ
central
nervou
system
thin
barrier
futur
mucos
vaccin
carrier
regardless
administr
rout
share
common
characterist
maintain
stabil
given
environ
mucoadhes
target
abil
specif
tissu
cell
